All News
Upadacitinib Effective in Biologic Refractory Psoriatic Arthritis
The SELECT-PsA 2 trial was presented at the ACR meeting and recently published in Annals of Rheumatic Disease, shows that psoriatic arthritis (PsA) patients who have failed at least one biologic DMARD, did respond well to upadacitinib.
Read Article
Medicare Physician Fee Schedule Final Rule Released
Centers for Medicare & Medicaid's CY 2021 Medicare Physician Fee Schedule final rule provides much-needed increases in Medicare reimbursement for the evaluation and management (E/M) services provided by rheumatologists and other cognitive care specialties to Medicare beneficiaries.
Read Article
Mortality in Low Dose Prednisone
Upon release of the new ACR 2020 Pharmacologic Treatment Recommendations for the Management of Rheumatoid Arthritis, many practitioners were surprised that the new guidelines recommended against glucocorticoid initiation at disease onset.
Read Article
Links:
Links:
Links:
#BestACR20Tweets RT @KDAO2011 : #FDA updates 6/16/20 canakinumab for AOSD 5/29/20 ixekizumab for nr-AxSpa 80 mg q4wks 3/9/20 nintedanib for progressive ILD 1/29/20 and 6/16/20 secukinumab nr-axSpa 150 mg q4wks, AS 300 mg SQ q4weeks 1/17/20 belimumab label for black pts removed
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links: